Dataset Information


Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.

ABSTRACT: BACKGROUND: The distinction between malignant and benign pleural effusions is a diagnostic challenge today and measuring soluble biomarkers could add to the diagnostic accuracy. Syndecan-1 is a proteoglycan involved in various cellular functions and is cleaved from the cell surface in a regulated manner. The shed fragment, which can be recovered in effusion supernatant and in serum, retains its binding capacities, but often with different functions and signalling properties than the cell-bound form. AIM: This study aimed to investigate the diagnostic and prognostic value of soluble syndecan-1 in pleural effusions and sera from patients with pleural malignancies. STUDY DESIGN: Using two cohorts of patients, we assessed the diagnostic and prognostic value of soluble syndecan-1 in pleural effusions and sera, using enzyme-linked immunosorbent assays. RESULTS: In pleural effusions, syndecan-1 distinguished malignant and benign diseases, with an odds ratio of 8.59 (95% CI 3.67 to 20.09). Furthermore, syndecan-1 in pleural effusions predicted a survival difference for patients with pleural metastatic disease and malignant mesothelioma of 11.2 and 9.2 months, respectively. However, no such effects were seen when syndecan-1 was measured in serum. CONCLUSION: Soluble syndecan-1 is a promising candidate biomarker for the cytopathological diagnosis and prognostication of malignant pleural effusions.


PROVIDER: S-EPMC4131558 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7464384 | BioStudies
2013-01-01 | S-EPMC3874014 | BioStudies
2011-01-01 | S-EPMC3070574 | BioStudies
2009-07-25 | GSE17310 | GEO
2013-01-01 | S-EPMC3749097 | BioStudies
2005-01-01 | S-EPMC1888495 | BioStudies
2014-01-01 | S-EPMC3945903 | BioStudies
2019-01-01 | S-EPMC6533224 | BioStudies
2014-01-01 | S-EPMC4190467 | BioStudies
| S-EPMC7542734 | BioStudies